Iovance Biotherapeutics (IOVA)

Common Shares
Sell: $2.54|Buy: $2.60|Change: 0 (0%)

Company profile

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Address

999 Skyway Road
Suite 150
San Carlos
CA
USA
94070


Telephone

+1 650 260-7120


Sector 

Healthcare


Previous key dates

NameKey Date
Iovance Biotherapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-02-27T16:30:00
Iovance Biotherapeutics Inc Fourth Quarter Earnings Results for 20252026-02-27T00:00:00
Iovance Biotherapeutics Inc Annual Report for 20252026-02-27T00:00:00
Iovance Biotherapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-06T08:30:00
Iovance Biotherapeutics Inc Third Quarter Earnings Result for 20252025-11-06T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T11:00:00
2025 Wells Fargo Healthcare Conference2025-09-05T08:00:00
Iovance Biotherapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-07T16:30:00
Iovance Biotherapeutics Inc Second Quarter Earnings Results for 20252025-08-07T00:00:00
Goldman Sachs Global Healthcare Conference2025-06-11T13:20:00
Iovance Biotherapeutics Inc Annual General Meeting for 20252025-06-10T11:00:00
Iovance Biotherapeutics Inc Webcast ASCO Event2025-05-31T19:15:00
Iovance Biotherapeutics Inc First Quarter Earnings Conference Call for 20252025-05-08T16:30:00
Iovance Biotherapeutics Inc First Quarter Earnings Result for 20252025-05-08T00:00:00
Barclays 27th Annual Global Healthcare Conference2025-03-13T09:30:00
TD Cowen's 45th Annual Health Care Conference2025-03-03T09:10:00
Iovance Biotherapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-02-27T16:30:00
Iovance Biotherapeutics Inc Fourth Quarter Earnings Result for 20242025-02-27T00:00:00
Iovance Biotherapeutics Inc Annual Report for 20242025-02-27T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.